The study examined the effectiveness of CAR-T cell therapy in 43 patients with central nervous system lymphoma (CNSL) treated between 2020 and 2024, focusing on patients with mutations in the TP53 gene, which are associated with a worse prognosis.[1] In patients with TP53 mutations (TP53+), the overall response rate was 64.5% and the complete response rate was also 64.5%, with a median overall survival of 14.07 months.[1] In comparison, patients without TP53 mutations (TP53-) achieved a higher overall response rate of 73.3% and a complete response rate of 69.2%, with a median overall survival of 33.47 months.[1] The study found that cell of origin (COO) classification was a key factor influencing long-term survival, with patients with non-germ-type TP53+ mutations having better outcomes than those with germ-type.[1] The researchers concluded that CAR-T cell therapy is an effective treatment for CNSL patients with TP53 mutations and may even be more effective in certain subgroups of patients.[1]